scholarly journals Low Positive Rates for HBeAg and HBV DNA in Rheumatoid Arthritis Patients—A Case-Control Study

Author(s):  
Yue Jia ◽  
Jingjing Zhang ◽  
Lingfei Mo ◽  
Bomiao Ju ◽  
Nan Hu ◽  
...  

Abstract Background The rates of hepatitis B virus (HBV) infection in rheumatoid arthritis (RA) patients were controversial when considering the reported outcomes. It was speculated that HBV infection status altered after suffering from RA, and variations over HBV infection rates became apparent. Methods To compare the positive proportions of hepatitis B e antigen (HBeAg) and HBV DNA, a case-control study was performed between the 27 chronic hepatitis B (CHB) patients with RA and the 108 age-and gender-matched CHB patients. In addition, the positive rates of hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) were surveyed among the 892 RA patients. Results Compared to the CHB patients, the CHB patients with RA exhibited lower rates of HBeAg positivity (11.1% vs. 35.2%, P = 0.003), HBV DNA positivity (37.0% vs. 63.9%, P = 0.007) and ALT elevation (11.1% vs. 35.2%, P = 0.024). In the 892 RA patients, the prevalence of HBsAg (3.0%) was lower than that of China national data (7.2%), whereas the anti-HBc positive rate of 44.6% was higher than that of 34.1%. Conclusion HBV infection status altered after suffering from RA. Compared to the matched CHB patients, low positive proportions of HBeAg and HBV DNA were observed for CHB patients with RA.

2016 ◽  
Vol 43 (5) ◽  
pp. 869-874 ◽  
Author(s):  
Valentina Varisco ◽  
Mauro Viganò ◽  
Alberto Batticciotto ◽  
Pietro Lampertico ◽  
Antonio Marchesoni ◽  
...  

Objective.Patients with resolved hepatitis B virus (HBV) infection, i.e., hepatitis B surface antigen (HBsAg)-negative/antihepatitis B core antigen (anti-HBc)-positive, undergoing rituximab (RTX)-based chemotherapy for hematological malignancies without anti-HBV prophylaxis are at risk of HBV reactivation, but the risk in such patients receiving RTX for rheumatological disorders is not clear. We evaluated this risk in HBsAg-negative/anti-HBc–positive patients with rheumatoid arthritis (RA) undergoing RTX without prophylaxis.Methods.Thirty-three HBsAg-negative/anti-HBc–positive outpatients with RA with undetectable HBV DNA by sensitive PCR assay [73% women, median age 60 years, 85% with HBsAg antibodies (anti-HBs), 37% with antihepatitis B envelope antigen] received a median of 3 cycles of RTX (range 1–8) over 34 months (range 0–80) combined with disease-modifying antirheumatic drugs (DMARD) without prophylaxis. All underwent clinical and laboratory monitoring during and after RTX administration, including serum HBsAg and HBV DNA measurements every 6 months or whenever clinically indicated.Results.None of the patients seroreverted to HBsAg during RTX treatment, but 6/28 (21%) showed a > 50% decrease in protective anti-HBs levels, including 2 who became anti-HBs–negative. One patient (3%) who became HBV DNA-positive (44 IU/ml) after 6 months of RTX treatment was effectively rescued with lamivudine before any hepatitis flare occurred. Among the 14 patients monitored for 18 months (range 0–70) after RTX discontinuation, no HBV reactivation was observed.Conclusion.The administration of RTX + DMARD in patients with RA with resolved HBV infection leads to a negligible risk of HBV reactivation, thus suggesting that serum HBsAg and/or HBV DNA monitoring but not universal anti-HBV prophylaxis is justified.


Hepatology ◽  
2012 ◽  
Vol 56 (3) ◽  
pp. 812-819 ◽  
Author(s):  
Wai-Kay Seto ◽  
Danny Ka-Ho Wong ◽  
James Fung ◽  
Ivan Fan-Ngai Hung ◽  
Daniel Yee-Tak Fong ◽  
...  

2016 ◽  
Vol 43 (11) ◽  
pp. 1197-1207 ◽  
Author(s):  
P. P. Gounder ◽  
L. R. Bulkow ◽  
M. Snowball ◽  
S. Negus ◽  
P. R. Spradling ◽  
...  

1997 ◽  
Vol 119 (3) ◽  
pp. 349-356 ◽  
Author(s):  
S. P. LUBY ◽  
K. QAMRUDDIN ◽  
A. A. SHAH ◽  
A. OMAIR ◽  
O. PAHSA ◽  
...  

To determine the prevalence and routes of transmission of hepatitis C virus (HCV) infection in Hafizabad, Pakistan, we collected sera in 1993 from a geographically based random sample of residents, and in 1994 identified 15 HCV-infected individuals (cases) and 67 age and sex matched uninfected individuals (controls). Initially we approached 504 households, and collected serum from a randomly selected household member in 309 (64%). Twenty persons (6·5%) had anti-HCV antibody; 31% percent had hepatitis B core antibodies, and 4·3% had hepatitis B surface antigen. In the case-control study, persons who received more therapeutic injections (categorized as averaging 1, 2–4, 5–9 or >10 injections per year in the previous 10 years) were more likely to be infected with HCV (odds ratio 0, 1·5, 2·5 and 6·9 respectively, P=0·008) compared to persons averaging 0 injections per year. Efforts to limit therapeutic injections to only those that are medically indicated and that use sterile equipment are essential in order to prevent transmission of HCV.


2020 ◽  
Vol 1 (6) ◽  
pp. 256-262
Author(s):  
Xun Qi ◽  
Qirong Jiang ◽  
Ying Lv ◽  
Sisi Yang ◽  
Jing Li ◽  
...  

Aim: Several host factors mediating immune response influence susceptibility to Hepatitis B Virus (HBV) infection, ability to clear the virus, and maintenance of a chronic state. Signal Transducer and Activator of Transcription 4 (STAT4) variations are correlated with the risk of developing autoimmune diseases. However, there have been few studies to assess the relationship between STAT4 variations and Hepatitis B surface Antigen (HBsAg) clearance in adults infected with HBV. Our aim was to evaluate the association between genetic variants in STAT4 and HBsAg clearance in a large sample size population. Methods: This case control study included Chronic Hepatitis B (CHB) (n = 1.688), HBsAg Clearance after Treatment (TC) (n = 170), HBV Uninfected (HC) (n = 1.012), and HBsAg Spontaneous Clearance (SC) (n = 1,052) patients. In the CHB group, patients were categorized into four subgroups: the Immune Tolerant (IT), Immune Active (IA), Inactive (IC), and Immune Reactivation (IR) phases, with 97, 855, 198, and 538 patients in each subgroup, respectively. Results: We found that the G allele in STAT4 rs7574865 was more frequent in the CHB and TC groups, compared with the SC group, whereas the STAT4 rs7574865 GG genotype was more frequent in the CHB and TC group, compared with the SC group in the dominant model. However, there was no statistical significance in genotype between TC and CHB, nor between the IT, IA, IC, and IR groups. Conclusions: The prevalence of the minor allele rs7574865 T was higher in subjects with spontaneously cleared HBV infections than in CHB patients.


2019 ◽  
Vol 6 (2) ◽  
pp. 70-75
Author(s):  
Mansour Bahardoust ◽  
Marjan Mokhtare ◽  
Arash Sarveazad ◽  
Shahdieh Karimi ◽  
Atefeh Talebi ◽  
...  

Background and aims: Hepatitis B virus (HBV) is one of the important public health diseases in Iran. Therefore, to control the prevalence of the disease, knowledge is required regarding the risk factor of HBV. Accordingly, the aim of this study was to determine the risk factors of HB transmission. Methods: A retrospective case-control study was conducted on the possible risk factors of HBV transmission. To this end, a total of 171 patients with HBV infection and 171 controls from Rasoul-eAkram hospital were investigated during 2015-2018. All subjects were directly evaluated using a faceto-face questionnaire about demographic aspects. Finally, HBV infection and its risk factors among the subjects were detected using hepatitis B surface antigen test. Results: Overall, 171 HBV patients including 77 (42%) males and 93 (58%) females were evaluated. The mean age of the participants was 40 ± 13 years. Univariate logistic analysis showed that HBV infection in these cases was associated with addiction injection (odds ratio [OR] = 4.08, CI:1.3- 9.57), family history (OR = 4.52, CI: 1.27-10.7), and having a history of blood transfusion (OR = 3.16, CI: 1.52-5.37). There were no significant relationships between the liver function tests, alcohol consumption, the history of dental visits, and HBV participants. In addition, the logistic-regression model proved that patients with a history of HBV-infected parents (At least one of them) and addiction injection were severely subject to HB infection. In other words, there was a significant association between a history of HBV-infected parents and addiction injection and HB infection. Conclusion: In general, HBV infection was strongly related to having a family member infected with hepatitis B, suffering from addiction injection, and having blood injection.


2019 ◽  
Author(s):  
Peng Wang ◽  
Yu Zhou ◽  
Lu Li ◽  
Yajie Gong ◽  
Rong Zhong ◽  
...  

Abstract Background: Recent studies reported that a hot genetic variant, rs641738 within the membrane bound O-acyltransferase domain containing 7(MBOAT7) and transmembrane channel-like 4 (TMC4) , was associated with several liver diseases. However, results are still conflicting. We conducted this study to explore the role of MBOAT7-TMC4 rs641738 in the risk of hepatocellular carcinoma (HCC) and persistent hepatitis B virus (HBV) infection. Methods: We first performed a case-control study by including 779 HCC cases and 1412 cancer-free controls. Controls are consisted of 678 HBV persistent carriers and 734 spontaneously recovered subjects. Rs641738 was genotyped by MassARRAY platform. Results were analyzed by multivariate logistic regression analysis under five genetic models. Second, we conducted a systematic review and meta-analysis to further explore the role of this variant in HCC risk. Results: Results suggested no association between MBOAT7-TMC4 rs641738 and HCC risk in most genetic models (All P > 0.05), although a marginally significant association was observed in TT vs. CC ( P = 0.037) and recessive model ( P = 0.044). Further meta-analysis including 2135 HCC cases and 4388 controls supported that this variant was not related to HCC risk, even in the TT vs. CC and recessive models. Besides, we identified that this variant also had no influence on persistent HBV infection. Conclusion: Our work highlights that MBOAT7-TMC4 rs641738 is not associated with the risk of HCC or persistent HBV infection. This study provides some clues to identify the “truth” of potential disease-related genetic factors in the post-genome era.


Sign in / Sign up

Export Citation Format

Share Document